Meerut Reporter

Hand Eczema Market to Exhibit Moderate Growth Rate till (2022-2032), Investigates DelveInsight | Key Companies – Leo Pharma, Japan Tobacco Inc., Incyte Corporation, Asana Biosciences

 Breaking News
  • No posts were found

Hand Eczema Market to Exhibit Moderate Growth Rate till (2022-2032), Investigates DelveInsight | Key Companies – Leo Pharma, Japan Tobacco Inc., Incyte Corporation, Asana Biosciences

November 14
23:45 2022
Hand Eczema Market to Exhibit Moderate Growth Rate till (2022-2032), Investigates DelveInsight | Key Companies - Leo Pharma, Japan Tobacco Inc., Incyte Corporation, Asana Biosciences
The Hand Eczema market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hand Eczema pipeline products will significantly revolutionize the Hand Eczema market dynamics.

DelveInsight’s “Hand Eczema Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hand Eczema, historical and forecasted epidemiology as well as the Hand Eczema market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Hand Eczema market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Hand Eczema market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hand Eczema Market Insights

 

Hand Eczema Overview

Hand Eczema (HE), also known as hand dermatitis, is one of the most common types of eczema and one of the most prevalent skin conditions worldwide. It mainly affects the palms but can also affect other parts of the hand. The severity of HE may range from very mild to severe and the course from acute to chronic, resulting in prolonged disability. The main symptoms are dryness, itching, scaly skin, and inflammation affecting the palm, or whole hand, including the fingers. Other symptoms may include cracking, soreness and bleeding.

 

Some of the key facts of the Hand Eczema Market Report: 

  • The Hand Eczema market size was valued at USD 11.5 Billion in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • The total prevalent cases of Hand Eczema were the highest in the US, with approximately 26,000,000 cases
  • Among EU5 countries, Germany had the highest number of prevalent cases of Hand Eczema (more than 7,000,00 cases) in 2021
  • Key Hand Eczema Companies: Leo Pharma, Japan Tobacco Inc., Incyte Corporation, Asana Biosciences, and others
  • Key Hand Eczema Therapies: Delgocitinib, Ruxolitnib, ASN002, and others
  • The Hand Eczema epidemiology based on gender analyzed that Hand Eczema is more prevalent in females as compared to males

 

Get a Free sample for the Hand Eczema Market Report 

 

Key benefits of the Hand Eczema Market report:

  1. Hand Eczema market report covers a descriptive overview and comprehensive insight of the Hand Eczema Epidemiology and Hand Eczema market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Hand Eczema market report provides insights on the current and emerging therapies.
  3. Hand Eczema market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Hand Eczema market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Hand Eczema market.

 

Download the report to understand which factors are driving Hand Eczema epidemiology trends @ Hand Eczema Epidemiological Insights 

 

Hand Eczema Market  

The dynamics of the Hand Eczema market are anticipated to change in the coming years owing to the expected launch of emerging therapies such and others during the forecasted period 2019-2032. 

“Currently, the only medication approved to treat hand eczema patients is Toctino (alitretinoin). It is commercially available in many EU countries, Canada, and South Korea and is indicated for use in adults with severe CHE that is unresponsive to treatment with potent topical corticosteroids. However, it is not approved in the US and Japan. Thus there is a significant urgent need for more effective and targeted options with better long-term side effect profiles.”

 

Hand Eczema Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Hand Eczema Epidemiology Segmentation:

The Hand Eczema market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Hand Eczema
  • Prevalent Cases of Hand Eczema by severity
  • Gender-specific Prevalence of Hand Eczema
  • Diagnosed Cases of Episodic and Chronic Hand Eczema

 

Hand Eczema Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hand Eczema market or expected to get launched during the study period. The analysis covers Hand Eczema market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hand Eczema Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Discover more about therapies set to grab major Hand Eczema market share @ Hand Eczema market forecast 

 

Hand Eczema Therapies and Key Companies

  • Delgocitinib: Leo Pharma/ Japan Tobacco Inc.
  • Ruxolitnib: Incyte Corporation
  • ASN002: Asana Biosciences

 

Hand Eczema Market Drivers

  • Widespread prevalence of the disease. 
  • Development of disease-specific treatments and novel therapeutic drug classes such as JAK inhibitors is likely to boost the market growth.

 

Scope of the Hand Eczema Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Hand Eczema Companies: Leo Pharma, Japan Tobacco Inc., Incyte Corporation, Asana Biosciences, and others
  • Key Hand Eczema Therapies: Delgocitinib, Ruxolitnib, ASN002, and others
  • Hand Eczema Therapeutic Assessment: Hand Eczema current marketed and Hand Eczema emerging therapies
  • Hand Eczema Market Dynamics:  Hand Eczema market drivers and Hand Eczema market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Hand Eczema Unmet Needs, KOL’s views, Analyst’s views, Hand Eczema Market Access and Reimbursement 

 

Hand Eczema Market Barriers

  • The emerging drugs have a significant opportunity, as there are no disease-specific approved therapies for the treatment of hand eczema in the United States
  • The current management of the disease includes only symptomatic treatments and does not treat the underlying cause of the disease.

 

Table of Contents 

1. Hand Eczema Market Report Introduction

2. Executive Summary for Hand Eczema

3. SWOT analysis of Hand Eczema

4. Hand Eczema Patient Share (%) Overview at a Glance

5. Hand Eczema Market Overview at a Glance

6. Hand Eczema Disease Background and Overview

7. Hand Eczema Epidemiology and Patient Population

8. Country-Specific Patient Population of Hand Eczema 

9. Hand Eczema Current Treatment and Medical Practices

10. Hand Eczema Unmet Needs

11. Hand Eczema Emerging Therapies

12. Hand Eczema Market Outlook

13. Country-Wise Hand Eczema Market Analysis (2019–2032)

14. Hand Eczema Market Access and Reimbursement of Therapies

15. Hand Eczema Market Drivers

16. Hand Eczema Market Barriers

17.  Hand Eczema Appendix

18. Hand Eczema Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Hand Eczema treatment, visit @ Hand Eczema Medications 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com